BA.5 variant detected in the Netherlands The BA.5 variant of the coronavirus SARS-CoV-2 was detected for the first time in the Netherlands this week.
Most reports received by MEBI in 2021 concerned copper IUDs More reports of suspected adverse effects from copper intrauterine devices (IUDs) were made in 2021 than in previous years, according to the annual report of the Dutch reporting and expertise centre for adverse effects of medical implants (MEBI).
RIVM recalls fill needles for COVID-19 vaccination at supplier’s request As of today, RIVM is recalling the fill needles made by MLS/Sol-Millenium Europe as a precaution, following a safety alert from the supplier. This applies to the SOL-M™ Blunt Fill Needle (REF 110022, LOT 05103013).
Collaboration necessary to ensure the safe reuse of consumer products In a circular economy, products, materials and raw materials are continually reused. For example, consumer products like clothes, packaging and toys.
At least 87% of people over 65 vaccinated at least once: high turnout, few regional differences Four months after the launch of the vaccination campaign, at least 87% of people over 65 in the Netherlands have been vaccinated against COVID-19 at least once.
Quality assessment of SARS-CoV-2 antigen test diagnostics: good performance at public test sites in the Netherlands In their role as WHO reference laboratories, RIVM and Erasmus UMC conducted a study on the quality of SARS-CoV-2 antigen diagnostics in the Netherlands.
Long-term symptoms more common after Lyme disease More than a quarter of people with Lyme disease continue to have long-term symptoms that lead to limitations in daily life even after treatment.
RIVM updates guidelines for AstraZeneca interval As of 21 May, RIVM updated the guidelines for the interval between two doses of the AstraZeneca vaccine. The interval can now be between 6 and 14 weeks.
Social well-being is improving, compliance with coronavirus measures remains important With the recent easing of the coronavirus measures, social contact and well-being are improving again. Compliance with most measures remains stable for now (such as getting tested by the GGD and avoiding crowds) or is decreasing very gradually.
Breast cancer screening resumes on Bonaire after COVID-19 hiatus Women aged 50 to 75 years on Bonaire can participate in the breast cancer screening programme again as of Wednesday, May 26, 2021. This was temporarily halted in 2020 due to the COVID-19 pandemic.